BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Business Intelligence

Andrii Buvailo, PhD

Science & Tech Communicator at www.AndriiBuvailo.com

Co-founder, BiopharmaTrend

   

Dr. Andrii Buvailo is a pharmaceutical industry analyst, tech scout and writer with a focus on artificial intelligence (AI) in drug discovery and biotech, digital transformation of pharma industry, and the advent of novel therapeutic modalities.

Andrii’s reports touch upon disruptive biotech startups, venture capital deals, drug discovery IPOs and platform companies. His articles were published on Forbes, and market research reports were referenced by some of the leading organizations (e.g. Deloitte).

Andrii is an ex-Enamine veteran, having served for the company as Director of E-commerce and Marketing for more than 8 years. Enamine is a global supplier of fine chemicals and compound libraries for the pharmaceutical industry.

Before venturing into the pharmaceutical industry and media entrepreneurship, Andrii used to work as a scientist. He holds PhD in Physical Chemistry, and has research experience in bioinorganic and supramolecular chemistry, thin polymer films, nanomaterials, and sensors.

Andrii is Ukrainian, currently based in Spain.


Recent articles from Andrii

Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?

Sept. 21, 2026      Business Intelligence
Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?

In the latest news, Novo Nordisk has entered a collaboration with Anthropic aimed at speeding the discovery and development of new medicines. An initial project will test Anthropic's Claude Science on specific R&D workflows where the companies expect the greatest …

The Bigger Point Beyond Insilico's Aging Research Milestone

Sept. 9, 2026      Business Intelligence
The Bigger Point Beyond Insilico's Aging Research Milestone

This week Insilico Medicine, an AI-driven drug discovery company, reported an unusual experiment. Arguably for the first time, aging biomarkers were written prospectively into a controlled trial run for a conventional disease indication. 

Six proteomic aging clocks were …

What Do the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences?

Sept. 5, 2026      Business Intelligence
What Do the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences?

Last week, Anthropic and OpenAI released new frontier models, specifically, Anthropic shipped Claude Fable 5.1 and a restricted variant called Mythos 5.1, while OpenAI shipped GPT-6 Astra.

OpenAI president, Greg Brockman went as far as suggesting this might …

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

July 2, 2026      Business Intelligence
Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent.

Everyone is talking about how Anthropic AI lab now designs drugs, hires the AlphaFold Nobel laureate, and ships Claude Science alongside Claude Code. Also, their partnership with Basecamp Research (i.e. EDEN-designed antibiotic …

Seven HealthTech Trends In Europe To Watch

June 26, 2026      Business Intelligence
Seven HealthTech Trends In Europe To Watch

I spent last week in Amsterdam, attending HLTH Europe 2026, arguably Europe's flagship healthcare innovation event, hosting more than 5,000 attendees. It is my second HLTH experience, and two additions to this year's program stood out: last year's Pharma & …

Is the Future of AI Drug Discovery Hybrid?

June 1, 2026      Business Intelligence
Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain). ALSO: several companies to watch in techbio space.

Everyone is talking about frontier AI models and agents. …

Is “Rescuing Failed Drugs with AI” a Category Now?

May 22, 2026      Business Intelligence
Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed...

In April, a Toronto-based startup called Biossil came out of stealth with a total of $70 million in funding, co-led by Peter Thiel’s Founders Fund …

Everyone is Launching AI Agents. What's Being Deployed?

April 4, 2026      Business Intelligence
Everyone is Launching AI Agents. What's Being Deployed?

A deep dive on the next cycle of biopharma's AI buildout

Last year's "growing buzz around AI agents" that we surveyed has since grown into a full avalanche of infrastructure commitments, partnerships, and agent launches across nearly every corner …

A New Combination Strategy Shows Up to 31.3% Weight Loss in Preclinical Study

Feb. 3, 2026   
A New Combination Strategy Shows Up to 31.3% Weight Loss in Preclinical Study

The modern obesity drug race has been defined by one word: incretins.

Blockbuster GLP-1 receptor agonists from companies like Novo Nordisk and Eli Lilly have reshaped both waistlines and Wall Street expectations. Drugs such as Semaglutide and Tirzepatide are …

FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss

Jan. 28, 2026      News
FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss

The U.S. Food and Drug Administration has cleared Life Biosciences’ Investigational New Drug application for ER-100, allowing the Boston-based biotechnology company to begin a Phase 1 clinical trial in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.